As we said earlier in the day, Pharmac’s decision to once again decline funding for a 12 month course of the breast cancer drug Herceptin is nothing short of a disgrace. The fact that it continues to deny New Zealand women an internationally standard treatment that is available in virtually every other OECD country is shameful, and yet another example of the public being let down by our drug buying agency.